Economic evaluation of monoclonal antibody in the management of colorectal cancer

Journal Title: Journal of Cancer Research & Therapy - Year 2013, Vol 1, Issue 1

Abstract

Objective: This study aims to determine the cost of colorectal cancer (CRC) management and compare the cost effectiveness of cetuximab and bevacizumab in the management of CRC. Method: This economic evaluation study from a societal perspective involves collecting resource utilization data based on the clinical pathway of colorectal cancer management. The cost calculated includes drugs, human resources, administrative, investigations as well as capital cost. Patient’s cost was also calculated based on an interview with colorectal cancer patients. Effectiveness estimates for monoclonal antibody (cetuximab and bevacizumab) treatment were modeled from study respondents based on references from other studies. Results: Cost of treating a case of colorectal cancer in stage I is RM13,623 (RM12,467-RM14,777), stage II RM19,753 (RM16,734-RM23,520), stage III RM24,972 (RM20,291-RM29,654) and stage IV RM27, 163 (RM23, 192-RM31,133). Cost of CRC management increase with the increasing stage of the disease (Kruskal Wallis, X2=106, p<0.001). Based on estimates of 2671 new cases of CRC, the incremental cost of cetuximab is RM20, 556 480 and bevacizumab is RM7,557,953 at 50% stage III and IV as compared to the conventional chemotherapy. The incremental cost per quality adjusted life years gained for cetuximab is RM38,869 and RM14,290 for bevacizumab. Although both types of monoclonal antibody are considered cost effective (based on WHO guidelines of less than three times of GDP), bevacizumab is considered more cost effective than cetuximab. Cost effectiveness was sensitive to the percentage of late stages of CRC. Conclusions: Cost of treating late stage of CRC is high and bevacizumab are more cost effective compared to cetuximab in the management of the late stage of CRC.

Authors and Affiliations

Ezat SW, Natrah MS, Aljunid S, Rizal MA, Saperi S, Ismail S, Fuad I, Azrif MA

Keywords

Related Articles

Skin rash in patients treated with neoadjuvant erlotinib (Tarceva) in resectable non-small cell lung cancer: Predictor for tumor response and survival?

Background: Skin rash during treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) has been reported to be predictive for response and survival in patients with advanced non-small cell l...

Primary peritoneal serous papillary carcinoma (PSPC) involving ovary and colon: Management and Treatment

We present a case report of a 47-year-old woman who was admitted to our University-Hospital following diagnosis of pelvic mass. Abdominal examination revealed a tender, palpable mass on the right iliac region. At the gyn...

Changing clinical picture of endemic Burkitt’s lymphoma with improved diagnostic technology: A systematic review

We evaluated the changes in anatomical locations of endemic Burkitt’s lymphoma (eBL) by systematic review. We compared the reports before ultrasound became a routine investigation in Burkitt’s lymphoma (BL) diagnosis wit...

Prognostic serum biomarkers for colorectal cancer – Review

Background: Colorectal cancer (CRC) is one of the most common malignancies in developed countries. Research for diagnostic and prognostic biomarkers is increasing. There are more than 750,000 papers indexed in PubMed dir...

Body composition, somatotype and risk of premenopausal breast cancer: a case-control study in Uruguay

In order to analyze detailed anthropometric characterisation for risk of breast cancer (BC) in premenopausal Uruguayan women, a case-control study was carried out at the Pereira Rossell Women’s Hospital, Montevideo, wher...

Download PDF file
  • EP ID EP549497
  • DOI 10.14312/2052-4994.2013-5
  • Views 68
  • Downloads 0

How To Cite

Ezat SW, Natrah MS, Aljunid S, Rizal MA, Saperi S, Ismail S, Fuad I, Azrif MA (2013). Economic evaluation of monoclonal antibody in the management of colorectal cancer. Journal of Cancer Research & Therapy, 1(1), 34-39. https://europub.co.uk./articles/-A-549497